Form 4: Bicara Therapeutics Director, Kate Haviland, Acquires Stock Options
SEC Form 4 Filing
Director Kate Haviland acquired stock options in Bicara Therapeutics Inc. on September 12, 2024.
Summary
- On September 12, 2024, Kate Haviland, a director of Bicara Therapeutics Inc., acquired 23,746 stock options.
- The exercise price of these options is $18.
- The options vest upon the earlier of August 16, 2025, or the date of the next Annual Meeting of Stockholders, contingent upon continued service.
- The options expire on September 12, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard regulatory filing related to stock option grants.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors and officers. This allows investors to monitor insider sentiment and potential alignment with company performance.
Stakeholder Impact
- The acquisition of stock options by a director may align their interests with those of shareholders, as the value of the options is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of transaction: Kate Haviland acquired stock options. |
| 08/16/2025 | Earliest vesting date for the stock options. |
| 09/12/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.